Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics' RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced that its precision oncology subsidiary, Ignite Proteomics, LLC (“Ignite” or “Ignite Proteomics”), has been featured in a peer-reviewed study published online ahead of print in npj Precision Oncology, a Nature journal. The study, led by investigators at Dana-Farber Cancer Institute, evaluated outcomes among patien.

Business Wire • Apr 20, 2026

Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC (“Ignite” or “Ignite Proteomics”). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein.

Business Wire • Mar 19, 2026

Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC (“Ignite”), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite's functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be cap.

Business Wire • Mar 13, 2026

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-8 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on March 9, 2026, the Company's common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company's stockholders at the r.

Business Wire • Mar 5, 2026

Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today shared its growth vision under the bitXbio™ strategy. bitXbio™ (pronounced “bit-by-bio”) is a transformational framework designed to connect public markets, blockchain and Web3, and digital asset treasuries for advancing breakthrough health innovations. The bitXbio™ strategy is intended to scale Aditxt as a social innovati.

Business Wire • Nov 18, 2025

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-113 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on November 3, 2025, the Company's common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company's stockholders at.

Business Wire • Oct 29, 2025

Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has begun enrollment in their prospective clinical study evaluating the Mitomic® Endometriosis Test (MET™), a novel blood-based diagnostic designed to aid in the early detection of endometriosis. The study, “Mitochondrial DNA Deletions in Plasma as a Diagnostic.

Business Wire • Oct 27, 2025

Evofem Announces Voting Results from Special Meeting of Stockholders

-- Evofem Shareholders Did Not Approve the Merger with Aditxt -- -- Evofem Pivots to Target National Listing for Stock, Growth Capital to Catalyze Net Sales -- SAN DIEGO , Oct. 20, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCID: EVFM) ("Evofem" or the "Company"), today announced that at a Special Meeting of Stockholders held this morning, its stockholders did not approve the proposal to adopt the Amended and Restated Merger Agreement dated July 12, 2024, as subsequently amended (the "Merger Agreement"), between the Company, Aditxt, Inc. (NASDAQ: ADTX), and Adifem, Inc., a wholly owned subsidiary of Aditxt, under which Aditxt intended to acquire Evofem. As a result, Evofem has exercised its rights to terminate the Merger Agreement.

PRNewsWire • Oct 20, 2025

Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms

-- 130% increase in traffic to PHEXXI.com, the website for Evofem's hormone-free prescription contraceptive PHEXXI® (lactic acid citric acid and potassium bitartrate) -- -- PHEXXI® is #1 most followed contraceptive brand on social media by healthcare providers -- SAN DIEGO , Sept. 11, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (Evofem) (OTCID: EVFM) today announced the conclusion and exciting impact of its groundbreaking August 2025 "Say Vagina" campaign, which aimed to normalize the use of clinical anatomical language and to combat the widespread censorship of essential medical terminology.

PRNewsWire • Sep 11, 2025

Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting

-- Special Meeting to be held on September 26, 2025 -- SAN DIEGO , Sept. 9, 2025 /PRNewswire/ -- In an update to stockholders today, Evofem Biosciences, Inc. ("Evofem" or the "Company") (OTCID: EVFM) anticipates the approval of the transactions (the "Merger") contemplated by the Amended and Restated Merger Agreement dated as of July 12, 2024, as amended, (collectively, the "Merger Agreement"), with Aditxt, Inc. (Nasdaq: ADTX) and Adifem, Inc., a wholly-owned subsidiary of Aditxt, at the Company's Special Meeting of Stockholders (the "Special Meeting") to be held on September 26, 2025.

PRNewsWire • Sep 9, 2025